Ultragenyx Q1 Loss Widens as Crysvita Sales Falter, Evkeeza and Dojolvi Rise
RARE•Ultragenyx reported a Q1 loss wider than analysts’ forecasts, driven by a seasonal Crysvita sales decline despite partial offset from Evkeeza and Dojolvi revenue growth. CFO Howard Horn and IR VP Joshua Higa will present at Bank of America’s Healthcare Conference on May 12 at 2:20 PM PT.
1. Wider Q1 Loss on Mixed Product Performance
Ultragenyx reported a Q1 loss that exceeded analysts’ estimates, driven by a seasonal decline in Crysvita sales. Evkeeza and Dojolvi both delivered revenue growth that partially offset the Crysvita shortfall, reflecting diversified product performance.
2. Bank of America Healthcare Conference Presentation
Howard Horn, CFO, and Joshua Higa, IR VP, will speak at Bank of America’s Healthcare Conference on May 12 at 2:20 PM PT. The fireside session will be available live and archived via the company's website webcast.
